mTOR Inhibition for Cancer Therapy: Past, Present and Future
108,00 €*
Sofort verfügbar, Lieferzeit: 1-3 Tage
Produktnummer:
9782817805573
This book describes the challenges involved in developing mTOR inhibitors for cancer treatment, starting with an in-depth examination of their molecular mechanism of action, with emphasis on the class side-effects, efficacy and mechanisms of resistance, as well as on promising novel directions for their development, including novel compounds and rational combinations with other anti-neoplastic drugs. Over the last 10 years, inhibitors of mTOR have emerged as a major class of anticancer drugs. Two rapamycin analogs are currently approved for the treatment of renal cell carcinoma, and it is estimated that a variety of other tumor types could benefit from mTOR inhibition, with numerous clinical trials (including pivotal registration trials) already underway. Second-generation small-molecule inhibitors of the pathway have also shown promise in terms of their superior tolerability and efficacy and are undergoing extensive clinical evaluation, with an estimated 30+ compoundscurrently under evaluation.
| EAN: | 9782817805573 |
|---|---|
| Sprache: | Englisch |
| Seitenzahl: | 308 |
| Produktart: | kartoniert, broschiert |
| Herausgeber: | Mita, Monica Rowinsky, Eric K. Mita, Alain |
| Verlag: | Springer Paris |
| Veröffentlichungsdatum: | 23.08.2016 |
| Größe: | 17 × 155 × 235 |
| Gewicht: | 470 g |
Verwandte Artikel
